Cocrystal Pharma's Preclinical Protease Inhibitor Effective Against Original, Two Variant COVID-19 Strains

Loading...
Loading...
  • Cocrystal Pharma Inc COCP has announced laboratory-based results for its lead preclinical SARS-CoV-2 3CL protease inhibitor, CDI-45205.
  • A third-party laboratory contracted by Cocrystal conducted in vitro studies evaluating the antiviral activity of CDI-45205 and its analogs in VeroE6-eGFP cells infected with SARS-CoV-2 (Wuhan strain), the U.K. variant (B.1.1.7), and the South African variant (B.1.351).
  • CDI-45205 and its analogs showed robust antiviral activity against both SARS-CoV-2 variants, surpassing the activity observed with SARS-CoV-2 (Wuhan strain).
  • Two reference inhibitors, including Gilead Sciences Inc's GILD remdesivir and Pfizer Inc's PFE PF-00835231, another SARS-CoV-2 3CL protease inhibitor, were included in the study as comparators.
  • CDI-45205 showed good bioavailability in mouse and rat pharmacokinetic studies via intraperitoneal injection and no cytotoxicity against various human cell lines. 
  • The Company recently demonstrated a strong synergistic effect with remdesivir. Additionally, a proof-of-concept animal study demonstrated that daily injection of CDI-45205 exhibited favorable in vivo efficacy in MERS-CoV-infected mice.
  • Price Action: COCP shares are up 11.2% at $1.39 during the premarket session on the last check Monday.
Posted In: BiotechNewsPenny StocksHealth CareGeneralBriefsCovid-19COVID-19 Vaccine
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...